ahr 5333 has been researched along with lidoflazine in 1 studies
| Studies (ahr 5333) | Trials (ahr 5333) | Recent Studies (post-2010) (ahr 5333) | Studies (lidoflazine) | Trials (lidoflazine) | Recent Studies (post-2010) (lidoflazine) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 229 | 37 | 14 |
| Protein | Taxonomy | ahr 5333 (IC50) | lidoflazine (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.0159 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 4.954 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, RJ; Johnson, CP; Proakis, AG; Shanklin, JR | 1 |
1 other study(ies) available for ahr 5333 and lidoflazine
| Article | Year |
|---|---|
Synthesis, calcium-channel-blocking activity, and antihypertensive activity of 4-(diarylmethyl)-1-[3-(aryloxy)propyl]piperidines and structurally related compounds.
Topics: Animals; Antihypertensive Agents; Aorta; Calcium; Calcium Channel Blockers; Hypertension; Male; Molecular Structure; Muscle Contraction; Piperidines; Rabbits; Rats; Rats, Inbred SHR; Structure-Activity Relationship | 1991 |